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ABSTRACT The QIAstat-Dx Respiratory Panel (QIAstat-Dx RP) is a multiplex in vitro 20 
diagnostic test for the qualitative detection of 20 pathogens directly from nasopharyngeal swab 21 
(NPS) specimens. The assay is a performed using a simple sample to answer platform with 22 
results available in approximately 69 minutes.  The pathogens identified are adenovirus, 23 
coronavirus 229E, coronavirus HKU1, coronavirus NL63, coronavirus OC43, human 24 
metapneumovirus A+B, influenza A, influenza A H1, influenza A H3, influenza A H1N1/2009,  25 
influenza B, parainfluenza virus 1, parainfluenza virus 2, parainfluenza virus 3, parainfluenza 26 
virus 4, rhinovirus/enterovirus, respiratory syncytial virus A+B, Bordetella pertussis, 27 
Chlamydophila pneumoniae and Mycoplasma pneumoniae. This multicenter evaluation provides 28 
data obtained from 1994 prospectively collected and 310 retrospectively collected (archived) 29 
NPS specimens with performance compared to the BioFire FilmArray Respiratory Panel version 30 
1.7. The overall percent agreement between QIAstat-Dx RP and the comparator testing was 31 
99.5%. In the prospective cohort, the QIAstat-Dx RP demonstrated a positive percent agreement 32 
of 94.0% or greater for detection of all but four analytes: coronaviruses 229E, NL63 and OC43, 33 
and rhinovirus/enterovirus. The test also demonstrated a negative percent agreement of ≥ 97.9% 34 
for all analytes. The QIAstat-Dx RP is a robust and accurate assay for rapid, comprehensive 35 
testing for respiratory pathogens.  36 
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 38 
INTRODUCTION  39 
Respiratory infections are common and contribute significantly to morbidity and 40 
mortality. They are also costly, being one of the leading reasons for healthcare visits (1, 2). 41 
Because infections with respiratory pathogens often result in symptoms that overlap between 42 
many causative agents, a definitive diagnosis requires laboratory testing. Therefore the approach 43 
of syndromic testing has been widely adopted with testing for multiple agents of upper 44 
respiratory infection at the same time with a single test. This panel-based approach can simplify 45 
ordering and laboratory workflow while improving sensitivity and time to result compared to 46 
older, conventional testing methods.  47 
From a clinical perspective, use of syndromic diagnostics can facilitate better 48 
antimicrobial stewardship by allowing antimicrobial or antiviral therapy to be given in a timely 49 
and appropriate manner (3, 4). The misuse of antibiotics in cases of viral respiratory infections is 50 
a common problem and a rapid result detecting a viral pathogen may prevent the unnecessary use 51 
of antibiotics. Rapid diagnosis of respiratory infections can also shorten times in the emergency 52 
room, decreased length of stay or prevent hospitalization and allow improved patient cohorting 53 
to prevent nosocomial infections (3, 5-9). 54 
The first multiplex respiratory panel was cleared by the FDA in 2009. This has been 55 
followed by a number of such syndromic assays.  These panels  vary in the number of analytes 56 
detected and the time to result but most are designed to be simple to use and require little hands 57 
on time (10). All current commercial multiplex assays of 5 or greater analytes include viral 58 
pathogens such as influenza A and B, respiratory syncytial virus, human metapneumovirus, 59 
adenovirus, parainfluenza virus, and rhinovirus/enterovirus. A smaller number of these panels 60 
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include bacterial pathogens such as Chlamydiophila pneumoniae, Mycoplasma pneumoniae and 61 
Bordetella species (10).   62 
In this study, data are presented for a multicenter clinical evaluation of a new multiplex 63 
respiratory panel, the QIAstat-Dx® Respiratory Panel (QIAstat-Dx RP).  The QIAstat-Dx RP is 64 
a multiplexed real-time PCR test intended for use with QIAstat-Dx system for the simultaneous 65 
qualitative detection and identification of multiple respiratory viral and bacterial nucleic acids in 66 
nasopharyngeal swabs (NPS) obtained from individuals suspected of respiratory tract infections. 67 
Each QIAstat-DX RP cartridge is run on an analyzer which consists of at least one analytical 68 
module for individual cartridge loading and one operational module with touch screen and 69 
integrated software. Up to 4 analytical modules can be connected with one operational module 70 
(Figure 1). The following pathogens types and subtypes are identified: adenovirus; coronaviruses 71 
229E, HKU1, NL63, OC43; human metapneumovirus A+B; influenza A; influenza A H1; 72 
influenza A H3; influenza A H1N1/2009; influenza B; parainfluenza viruses 1, 2, 3, and 4; 73 
rhinovirus/enterovirus; respiratory syncytial virus A+B; Bordetella pertussis; Chlamydophila 74 
pneumoniae; and Mycoplasma pneumoniae. Testing was performed on residual NPS collected in 75 
transport media. Both a prospective and retrospective arm of the study are included. For all 20 76 
analytes, performance calculations are based on comparison to an FDA-cleared/approved test. 77 
 78 
MATERIALS AND METHODS 79 
 Prospective Clinical Specimens. The study was conducted at six geographically distinct 80 
sites in the U.S. and Europe (Nationwide Children’s Hospital – Columbus, OH, Hennepin 81 
County Medical Center – Minneapolis, MN, Indiana University School of Medicine – 82 
Indianapolis IN, Laboratory Alliance of Central New York – Liverpool, NY, TriCore Reference 83 
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Laboratories – Albuquerque, NM, and University of Copenhagen - Hvidovre, Denmark). 84 
Specimens were prospectively enrolled over a period of approximately 17 months (December 85 
2017-April 2019) and tested either fresh or after being frozen at ≤-70°C. Specimens meeting the 86 
following inclusion criteria were selected: specimen was an NPS collected in transport media for 87 
standard of care (SOC) testing.  The  transport media used in this study were as follows: 88 
Universal Transport Medium, Copan Diagnostics, Brescia, Italy and CA, USA; MicroTest M4, 89 
M4RT, M5, M6, Thermo Fisher Scientific, MA, USA; BD Universal Viral Transport, Becton 90 
Dickinson, NJ, USA; Universal Transport Medium, HealthLink Inc., FL, USA; Universal 91 
Transport Medium, Diagnostic Hybrids, OH, USA; V-C-M Medium, Quest Diagnostics, NJ, 92 
USA; UniTranz-RT Universal Transport Media, Puritan Diagnostics, ME, USA. The specimen 93 
had to have adequate residual volume (≥2.0mL for U.S. sites and ≥1.5mL for Hvidovre 94 
Hospital), and had been held at room temperature for less than or equal to 4 hours, at 4°C for less 95 
than or equal to three days, or at -20°C or -70°C frozen for more than three days before 96 
enrollment. A waiver of informed consent requirement was obtained from the Institutional 97 
Review Boards (IRBs) at each study site for the use of residual deidentified NPS specimens.   98 
Retrospective (Archived) Clinical Specimens. Preselected frozen archive specimens 99 
were enrolled based on identification of specific positive targets using SOC testing at each study 100 
site. Specimens were thawed and tested at each study site, in blinded fashion, with both the  101 
QIAstat-Dx RP  and the comparator assay, BioFire FilmArray Respiratory Panel version 1.7 102 
(FARPv1.7). If the comparator assay did not confirm the preselected target as positive, the 103 
specimen was excluded from the data analysis for that target. 104 
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Clinical and demographic data. Data were collected for both prospective and 105 
retrospective specimen; the information included hospitalization status at the time of specimen 106 
collection, date of specimen collection, subject sex, and subject age at time of collection. 107 
QIAstat-Dx Respiratory Panel. The panel includes testing for detection of adenovirus, 108 
coronavirus 229E (CoV 229E), CoV HKU1, CoVNL63, CoV OC43, human metapneumovirus 109 
A+B (hMPV), influenza A (FLU A), FLU A H1, FLU A H3, FLU A H1N1/2009, influenza B 110 
(FLU B), parainfluenza virus 1 (PIV 1), PIV 2, PIV 3, PIV 4, human rhinovirus/enterovirus 111 
(RV/EV), respiratory syncytial Virus A+B (RSV), Bordetella pertussis, Chlamydophila 112 
pneumoniae and Mycoplasma pneumoniae. Approximately 300 l of specimen was tested  113 
according to manufacturer’s instructions (11). The QIAstat-Dx Respiratory Panel Cartridge  and 114 
platform consists of automated nucleic acid extraction, reverse transcription, polymerase chain 115 
reaction (PCR), and fluorescence detection with results analysis in approximately 69 minutes per 116 
run (i.e., per specimen); Figure 1 shows the instrument workflow. The PCR is run to 40 cycles 117 
and the fluorescence readings are analyzed by the Result Calling Algorithm (RCA) to determine 118 
positive or negative calls.  The cartridge includes a full process Internal Control which is titered 119 
MS2 bacteriophage in dried form that is rehydrated upon specimen loading. This control material 120 
verifies all steps of the analysis process.  121 
The QIAstat-Dx RP Analyzer performs automated result analysis with each target in a 122 
valid run reported as positive or negative.  The qualitative results are displayed on the instrument 123 
screen and can be printed. If the internal control fails, the software automatically will provide a 124 
result for targets that test positive but the other panel targets will result as ‘Invalid’. Within the 125 
software is a report to display the amplification curve for each target, for which the cycle 126 
threshold (Ct) and endpoint fluorescence value are provided on the final printed report.  This 127 
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study was conducted with an Investigational Use Only (IUO) version of the QIAstat-Dx RP that 128 
is identical to the final FDA-cleared/CE-IVD marked version.   129 
ComparatorTesting. Comparator testing consisted of FilmArray Respiratory Panel 130 
version 1.7 (FARPv1.7) testing for all targets, with testing performed at the source laboratory. 131 
The assay detects adenovirus, coronavirus 229E, coronavirus HKU1, coronavirus NL63, 132 
coronavirus OC43, human metapneumovirus, influenza A, influenza A H1, influenza A H3, 133 
influenza A H1-2009, influenza B, parainfluenza virus 1, parainfluenza virus 2, parainfluenza 134 
virus 3, parainfluenza virus 4, rhinovirus/enterovirus, respiratory syncytial virus, Bordetella 135 
pertussis, Chlamydophila pneumoniae and Mycoplasma pneumoniae. 136 
Results and Discrepant Analysis. A QIAstat-Dx Respiratory Panel result was considered a true 137 
positive (TP) or true negative (TN) only when it agreed with the result from the comparator 138 
method (FARPv1.7). Discrepant analysis ensued when results were discordant, i.e. false positive 139 
(FP) or false negative (FN) results.  140 
Discrepant analysis for all panel targets excluding Bordetella pertussis was performed 141 
using the NxTAG® Respiratory Pathogen Panel on the Luminex® MAGPIX® Instrument, at 142 
one clinical study site (Indiana University School of Medicine).  For B. pertussis discordant 143 
analysis, the VERIGENE® Respiratory Pathogens Flex Test (RP Flex) was used to detect and 144 
differentiate the following Bordetella species, Bordetella parapertussis/bronchiseptica, 145 
Bordetella holmesii, and Bordetella pertussis. This testing was performed at one clinical study 146 
site (Laboratory Alliances of Central New York).  147 
Note that the performance data for sensitivity/positive percent agreement (PPA) and 148 
specificity/negative percent agreement (NPA) presented in this manuscript consist of unresolved 149 
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data as presented in the package insert for the FDA-cleared test; discrepancy investigation is 150 
provided but was not used to recalculate performance data. 151 
Workflow and Time to Results:  152 
For workflow analysis, the operating procedures were compared to determine differences 153 
in the number of steps required for set up (11, 12).  A total of 20 specimens were set up for 154 
analysis by both methods and the time required from beginning set up to loading into the 155 
instrument was timed. In addition, a random sampling of 50 results generated on the same 156 
specimen run on the QIAstat-Dx RP and the FARPv1.7 was analyzed and the average time to 157 
result for each platform was calculated. 158 
Statistical Analysis.  Binomial two-sided 95% confidence intervals were calculated 159 
using the Wilson Score Method. Differences in median Ct values were determined using Mood’s 160 
median test. 161 
 162 
RESULTS 163 
Demographics. A total of 2,304 specimens (1994 prospective and 310 retrospective) 164 
were included in data analysis for both arms of the study collected from a range of 165 
geographic/demographic populations (Table 1). Overall, specimens included slightly more 166 
female than male subjects (53%, 1,222/2,304 and 47%, 1,082/2,304, respectively). The 167 
specimens were from various age groups: 33% of the specimens were from children aged 5 and 168 
under, 14% were from those aged 6-21, 17% were from adults aged 22-49, and 36% were from 169 
adults over the age of 50.  For treatment setting, 32.7%, (754/2,304) were obtained from 170 
hospitalized patients, 3.3% (75/2304) from those visiting the emergency department, 7.0% 171 
(161/2,304) were admitted to the ICU and 43.9 % (1,012/2,304) were obtained from subjects 172 
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seen in an outpatient setting. For 302 (13.1%) specimens, the location was other than those listed 173 
or unknown. 174 
QIAstat-Dx RP test performance. There were a total of 2,342 specimens originally 175 
enrolled for both arms of the study (prospective – 2018 [1,111 frozen, 907 fresh; retrospective] – 176 
324 archived frozen). A total of 24 prospective specimens were excluded for reasons related to 177 
sample stability or test performance. Fourteen retrospective samples were withdrawn because the 178 
target of interest did not confirm on repeat testing with the comparator assay (FARPv1.7). 179 
Of the 1,994 prospective specimens tested and analyzed during the clinical evaluation, 180 
95.9% (1,912/1,994) yielded valid results on the first attempt (i.e., first loaded cartridge). Invalid 181 
or no result were obtained for the remaining 82 specimens (4.11%). Forty-two (42) specimens 182 
were invalid due to cartridge internal control failure (2.11%). Of these, 20 (1.00%) provided a 183 
result for positively detected targets and 22 (1.10%) had no detections. For 40 (2.00%) 184 
specimens no results were obtained due to incomplete runs. Of these, one specimen was aborted 185 
by the user (0.05%), 21 were due to instrument errors (1.05%) and 18 were due to cartridge 186 
related errors (0.90%).  187 
Seventy-two (72) of the 82 initially failed (no results or invalid) specimens yielded valid results 188 
after a single retesting using a new cartridge/specimen. The remaining 10 specimens failed on 189 
the second attempt: two due to cartridge failures, one due to instrument errors and seven due to 190 
internal control failures. Of these internal control failures, detected pathogens were reported for 191 
four specimens. Thus six samples (6 of 1994 = 0.3%) did not provide valid results after a single 192 
retest, yielding a 99.7% success rate after a single retest. 193 
Summary of QIAstat-Dx RP findings.  194 
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Prospective Specimens. The QIAstat-Dx RP detected at least one analyte in 1166 of 195 
1,994   specimens tested, yielding an overall positivity rate of 58.5% (Table 1) The highest 196 
detection rate was seen in young children (≤ 5 years of age; 24.1%) followed by those >50 years 197 
of age (19.5%).  198 
The summary of prospective performance characteristics for individual QIAstat-Dx RP 199 
targets is presented in Table 2. PPA and NPA were calculated with respect to the comparator 200 
method along with 95% CI. The QIAstat-Dx RP demonstrated a PPA of 91.2% or greater for all 201 
but three analytes. For FLU A H1, no PPA could be calculated. The three analytes demonstrating 202 
a PPA ˂ 91.2%: - all were CoV:  CoV 229E (88.9%), CoV NL63 (85.1%), and CoV 43 (89.7%). 203 
Additionally, nine analytes demonstrated a lower bound of the two-sided 95% CI ˂ 80.0% due to 204 
few or no observations in the study. Overall, the QIAstat-Dx RP demonstrated a NPA of ≥ 205 
97.9% for all analytes, with lower bounds of the two-sided 95% CI of ≥ 97.1%. 206 
The QIAstat-Dx RP detected a total of 191 specimens with distinctive multiple organism 207 
detections representing 9.6% of all prospective samples. There were 166 double infections, 22 208 
triple infection and 3 quadruple infections. The rate of multiple detection by age groups was: 209 
79.1% (151/191) for <6 years; 6.3% (12/191) for 6-21 years; 7.3% (14/191) for 22-49 years; and 210 
7.3% (14/191) for >49 years. The three pathogens most prevalent in the multiple detections were 211 
RV/EV (108/191, 56.5%), RSV (77/191, 40.8%) and adenovirus (53/191, 27.7%).  212 
Retrospective Specimens. Performance characteristics for the retrospective specimens 213 
are presented in Table 3. The QIAstat-Dx RP detected at least one analyte in 299 of 310   214 
specimens tested, yielding an overall positivity rate of 96.5% (Table 1). For the 11 negative 215 
samples, comparator testing was positive for the pathogen of interest, with retesting accruing on 216 
same freeze-thaw cycle as the testing with QIAstat-Dx RP. With this smaller archived sample 217 
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set, PPA was >90% for all but 4 targets. Also, the lower bounds of the 95% CI for the PPA were 218 
lower than the prospective group due to fewer samples tested. Values for NPA were all above 219 
95% for all 20 targets. As these samples were pre-selected, prevalence was not evaluated.  220 
Comparator Analysis and Discrepancy Investigation. There were a total of 45,895 221 
analyzable QIAstat-Dx RP pathogen results for the 2,304 specimens (prospective and 222 
retrospective). The overall percent agreement between QIAstat-Dx RP and the comparator 223 
testing was 99.5% (45,662/45,895). There were 2,075 detected pathogen results with the 224 
QIAstat-Dx RP; the comparator method was positive for 2,026 pathogen detections. The overall 225 
PPA with respect to the comparator method was 95.5%% (1,934/2,026). Data for the median Ct 226 
values for all positive detections for the QIAstat-Dx RP are presented in the supplemental 227 
material (Table S1). 228 
There were 43,871- “not detected” results with the QIAstat-Dx RP; the comparator 229 
method was negative for 43,920 analytes. The overall NPA with respect to the comparator 230 
method was 99.7% (43,728/43,869).  231 
For the viral analytes, QIAstat-Dx RP detected a total of 1,923 viral analytes compared to 232 
1,880 for FARPv1.7. Using the comparator as truth, the overall PPA and NPA were 95.5% 233 
(1,795/1,880) and 99.7% (32,101/32,117) respectively. Using the comparator as truth, the overall 234 
PPA and NPA were 92.3% (36/39) and 99.9% (6402/6409) respectively for all bacterial targets.  235 
Using comparator testing as the true result, there were 141 FP detections and 92 FN 236 
detections overall; additional discrepancy analysis was performed for 214 (91.8%) of these false 237 
detections. For 62 of the 141 FP cases (44%), along with 30 of the 92 FN cases (33%), there was 238 
supportive evidence for the QIAstat-Dx RP result, bringing the adjudicated overall concordance 239 
 o
n
 April 8, 2020 by guest
http://jcm.asm.org/
D
ow
nloaded from
 
12 
  
 
for the positive and negative results to 98.5% and 99.7%, respectively. A summary of the 240 
discrepancy investigation is presented in Table 4.  241 
Workflow and time-to-results. A review of the procedure showed that the steps for the 242 
set up the pouches up to loading in the instrument did differ between the two platforms with the 243 
specimen being pipetted directly into the QIAstat-Dx while the FA RPv1.7 required addition of 244 
both sample and a diluent using injection vials for reagent hydration and sample preparation in 245 
addition to a transfer pipette for manipulating the specimen.  Timed studies for set up of 20 246 
pouches by two operators from specimen to loading took on average 35 seconds for the QIAstat-247 
Dx RP and 115 seconds for the FARPv1.7. 248 
The average time to results for the 50 paired runs was as determined by each instrument was 249 
69.1± 0.8 mins for QIAstat-Dx RP and 63.4 ± 0.5 mins for FARPv1.7. 250 
DISCUSSION  251 
This evaluation of the QIAstat-Dx RP demonstrated the performance of the test in a large 252 
multicenter study using 2,304 residual NPS specimens with 45,895 results generated.  This new 253 
respiratory multiplex panel can be used to aid in diagnostic testing of respiratory infections. In 254 
this trial, the number of prospective positive detections was relatively high for most pathogens 255 
with the exception of CoV 229E, PIV 4, and B. pertussis (all with N<5). No detections were 256 
found for C. pneumoniae, PIV 1 and FLU A H1, which was not circulating during the study 257 
period. The QIAstat-Dx RP testing system was shown to be reliable with few failures (95.3% 258 
success on the initial test attempt for the prospective samples tested) and rapid with results 259 
available in approximately 69 minutes. The data presented here along with testing of contrived 260 
specimens were used as part of the regulatory submissions for the  QIAstat-Dx RP which 261 
received de novo 510 (k) clearance in the U.S. in May 2019 (11). 262 
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Taken in total, the QIAstat-Dx RP performance was comparable to the FARPv1.7 with an 263 
overall percent agreement of 99.5%. In the prospective cohort, the QIAstat-Dx RP demonstrated 264 
a PPA of 94.0% or greater for detection of all but four analytes: CoV 229E, NL63, and OC43, 265 
and RV/EV. The test also demonstrated a NPA of ≥99.6% for all analytes. The discordant 266 
analysis showed that both assays appear to generate “false” results as would be expected. The 267 
NxTAG assay used for discordant analysis is very similar to both these assays being a multiplex 268 
respiratory panel. So for the discordant analysis, truth was determined by a best of two out of 269 
three test results. 270 
Viruses are a common cause of respiratory infections in both adult and pediatric 271 
population which was also seen in our study cohort. While the QIAstat-Dx RP had a higher 272 
number of positive viral detections overall compared to FARPv1.7 (1,645 versus 1,610), for 273 
individual targets, there was increased sensitivity found with both assays depending on the 274 
analyte.  Viral detections were notably higher than those of the bacterial targets among the 275 
prospective specimens (1645 viral vs. 39 bacterial detections). 276 
Rhinovirus/Enterovirus. The most common viral analyte was RV/EV with a total of 304 277 
positive detections. The extensive diversity within the rhinoviruses means that most molecular 278 
assays, including QIAstat-Dx RP and the comparator assay, target the 5′UTR. This region is 279 
highly conserved among all rhinoviruses and enteroviruses, causing cross-reactivity between 280 
assays for the two viruses and making their differentiation difficult (13). RV/EV was also the 281 
target showing the highest number of discordant results. The discordant specimens were 282 
analyzed with the NxTAG® Respiratory Pathogen Panel, another FDA-cleared multiplex that 283 
targets the 5’UTR. Therefore, no definitive resolution of the type of virus (rhinovirus versus 284 
enterovirus) was made for the FP and FN samples.  285 
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Adenovirus.  For adenoviruses, QIAstat-Dx RP is designed to detect genogroups B, C, 286 
and E, the types most commonly associated with respiratory infections. It will also detect, to 287 
some degree,  genotypes A, D, F and G as evidenced by contrived testing with typed strains (11). 288 
The FARPv1.7 was also designed for detection of genotypes B, C, and E. Both tests use the 289 
hexon gene as the target. The differences in performance between these two tests in the present 290 
study may related to specific primer and probe sequence differences or the level of sensitivity 291 
and specificity of the assays for the many different serotypes of adenovirus (Prior studies have 292 
demonstrated that a significant number of adenoviruses from upper respiratory samples may be 293 
in genogroups A, D, and F and could be missed by tests that are not designed for broad coverage 294 
of adenoviruses. (14, 15). Some recent data suggest that broadened inclusivity targeting the non-295 
respiratory types may improve clinical assay performance (16). 296 
Coronavirus. The QIAstat-Dx RP assay has 4 distinct targets for detection of CoV. Three 297 
of four of these targets (Table 2) had PPA <90% which were the lowest for all analytes in the 298 
prospective analysis.  In contrast, the retrospective CoV specimens showed better positive 299 
agreement with all targets > 96% (Table 3).  It is unclear why there were differences in 300 
performance in the two arms of the study.  There were a relatively low number of positive 301 
detections in general. In addition, the FP sample did have significantly higher Ct values than the 302 
TP for all samples (Supplemental Table 1), suggesting that the FP were related to low level of 303 
virus. The level of virus in these FN specimens cannot be estimated as no semi-quantitative value, 304 
such as Ct, is provided with the FARPv1.7.  305 
Influenza viruses. Among the viruses detected in this multiplex panel, there is substantial 306 
evidence that the rapid molecular diagnosis of influenza virus infections impacts patient 307 
outcomes for both adult and pediatric populations (3, 6, 9). The QIAstat-Dx RP has a total of 4 308 
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targets for detection of FLU A: a pan-influenza A target and specific targets for 3 subtypes - 309 
Influenza A H1, Influenza A H1 2009, and Influenza A H3. Of the 251 Influenza A positive 310 
detections, a total of 248 (98.8%) had additional subtype specific detections (85 specific 311 
detections for H1N1 2009 and 163 for H3). There were no detections of seasonal H1N1. Three 312 
(1.2%) Influenza A positives had no associated specific detections. This could be due to virus 313 
levels below the limit of detection for the type specific assays. However, it could indicate the 314 
detection of a novel influenza A type and this should be considered when seen in clinical use.(17, 315 
18) For FLU B virus there is a single target designed to detect the two sublineages of the virus 316 
[B/Victoria/2/87–like (Victoria lineage) and B/Yamagata/16/88–like (Yamagata lineage)]. There 317 
were 7 FN results with the QIAstat-Dx RP and 1 with FARPv1.7, which may reflect differences 318 
in sensitivity related to the viral strains. Because the comparator does not provide any semi-319 
quantitative value it is difficult to determine the relative level of virus in the 7 QIAstat-Dx FN;  320 
however, the 1 FN for the FARPv1.7 had a Ct value of 20.4, suggesting it did have a significant 321 
amount of virus present. 322 
A relatively low number of bacterial detections were found in the prospective cohort as 323 
has been seen in other studies with multiplex testing (16, 19).   The most common of the 324 
bacterial targets was M. pneumoniae with 24 detections, more than the 19 detected with 325 
FARPv1.7. However, it should be noted that use of an NP specimen for detection of M. 326 
pneumoniae may be suboptimal particularly when diagnosing lower respiratory tract infection 327 
(20, 21). For B. pertussis, discrepancy between the QIAstat-Dx RP   and the comparator method 328 
were not unexpected as the QIAstat-Dx RP targets the multi-copy insertion sequence (IS481) 329 
which is present in several Bordetella species (B. pertussis, B. holmesii, and B. bronchiseptica) 330 
whereas the comparator targets the single-copy promoter region of the pertussis toxin gene and is 331 
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designed to be specific to the detection of B. pertussis. Use of the single-copy toxin gene target 332 
has been shown to be less sensitive than IS481 (22, 23). The assay used for discordant analysis 333 
calls out the individual Bordetella species (B. pertussis, B. parapertussis and B. holmesii). The B. 334 
pertussis target is also the toxin promoter region so would be a single-copy gene. There were a 335 
total of 6 QIAstat-Dx RP FP results for B pertussis for both arms of the study (Table 4). Five of 336 
these samples were available for further analysis; only one (1) confirmed using the discordant 337 
testing with at Ct value of 31.6. In examining the Ct values for the all detections in the clinical 338 
trial, the discordant detections had a significantly higher median Ct value than the concordant 339 
positive detections (TP median Ct =26.2 vs. FP median Ct =33.0, p value=0.008, TABLE S1). 340 
Thus some of the FP may have been missed by both the comparator and discordant analysis 341 
assays based on the lower sensitivity of a single copy gene target.  342 
As with other multiplex respiratory panels, the QIAstat-Dx RP allows for detection of 343 
multiple pathogens representing co-infections. The rate of co-detections was highest in the 344 
pediatric patients <6 years of age and the most common analytes in the codetections were 345 
RV/EV, RSV and adenovirus. Similar findings have been reported for other multiplex respiratory 346 
panels (16, 19).  More data is needed on the impact of codetections on outcomes however it may 347 
be useful for infection control purposes to allow better cohorting or isolation of infected patients 348 
(24).   349 
The QIAstat-Dx RP workflow is very simple and the footprint of the instruments is small 350 
measuring 20.3cm(width) x 32.6cm (height) x 51.7cm  (depth) for 1 Operational Module plus 1 351 
Analytical module (8.0in w x 12.8in h x 20.4in d; see Figure 1). In comparison to FARPv1.7, 352 
QIAstat-Dx RP involves only one step to pipette the specimen into the cartridge for loading as 353 
there is no buffer added nor any other manipulations required. This lessens manipulation and 354 
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may help to reduce contamination. The run times are similar lasting on average 69 and 63 355 
minutes for the QIAstat-Dx RP and FARPv1.7 respectively. Both platforms allow for testing of 356 
one pouch at a time per module.  In terms of reliability, the initial rate of invalid or no results on 357 
first testing for the prospective samples was 4.1% and after a second test 0.7%  This invalid rate 358 
is comparable  to other multiplex platforms currently available (16). A significant benefit of the 359 
system allows the user to obtain a Ct value for each detected pathogen and the internal control. 360 
The comparator assay does not allow the user to see Ct values. These values, while not truly 361 
quantitative, do allow a semi-quantitative assessment of target amount that can be useful in 362 
trouble-shooting or other quality control measures.  363 
There are some limitations with this study. For the prospective arm, some specimens 364 
were tested fresh but some were frozen at ≤ -70°C prior to testing. However, data indicated that 365 
the frozen storage did not significantly affect performance (11). The study period bridges 17 366 
months and includes two respiratory seasons; however variations in circulating strains, 367 
particularly influenza A viruses, may be limited. Because the prevalence of some analytes was 368 
low in the prospective cohort, frozen retrospective samples where used to increase the numbers 369 
for positive detections. As stated above, freeze thawing did not appear to affect performance in 370 
terms of prevalence. However for the retrospective samples, all were tested with both the test and 371 
comparator assays on the same freeze-thaw cycle to remove this as a confounder.  Overall the 372 
percentage of discrepant results versus the comparator methods was low.  373 
In summary, the QIAstat-Dx RP demonstrated good comparative performance in this 374 
large multicenter clinical trial and represents a new alternative for multiplex respiratory testing. 375 
It is a robust and accurate assay for rapid and comprehensive testing for respiratory pathogens 376 
from nasopharyngeal swab specimens.  377 
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FIGURE 1  QIAstat-Dx Respiratory Panel Assay Workflow  466 
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TABLE 1 Demographics and Positivity Rate for QIAstat-Dx Respiratory Panel: For all 467 
Prospective and Retrospective Samples and By Age Groupings 468 
 Prospective Samples  
(n=1994) 
Retrospective Samples  
(n=310)
a
 
Demographics and Location 
 No. % of Total No. % of Total 
Male 924 46.3 158 50.8 
Female 1070 53.7 152 49.2 
     
Outpatients 788 39.5 224 72.3 
Hospitalized 686 34.4 68 21.9 
Emergency 67 3.4 8 2.6 
ICU 153 7.7 8 2.6 
Other/Unknown 300 15.0 2 0.6 
 
Overall Positivity and Co-detections 
 No. % of Total No. % of Total 
Negative Samples 828 41.5 11 3.5 
Positive Samples 1166 58.5 299 96.5 
Single Detections 800 
 
40.1 222 71.6 
Co-Detections 366 18.4 77 24.8 
     
Positivity by Age Grouping 
 No. % of Total No. % of Total 
≤5 years (n=627) 481 24.1 137 44.2 
6-21 years (n=239) 123 6.2 80 25.8 
22-49 years (n=330) 174 8.7 48 15.5 
50+ years (n=798) 388 19.5 34 11.5 
a
All retrospective samples were chosen from frozen archives based on initial standard of care 469 
testing and retested with the  QIAstat-Dx RP  and comparator.  470 
 471 
  472 
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TABLE 2 Performance Summary of the QIAstat-Dx Respiratory Panel for Prospective 473 
Specimens
a
  474 
Analyte 
 Positive Percent Agreement Negative Percent Agreement 
Nb TP/(TP + FN) % 95%CI TN/(TN + FP) % 95%CI 
Viruses 
Adenovirus 1986 86/90 95.6 89.1-98.3 1880/1896 99.2 98.6-99.5 
Coronavirus 229E 1984 8/9 88.9 56.5-98.0 1975/1975 100 99.8-100.0 
Coronavirus HKU1 1984 51/52 98.1 89.9-99.7 1925/1932 99.6 99.3-99.8 
Coronavirus NL63 1985 40/47 85.1 72.3-92.6 1936/1938 99.9 99.6-100.0 
Coronavirus OC43 1984 26/29 89.7 73.6-96.4 1951/1955 99.8 99.5-99.9 
Human Metapneumovirus 1985 115/122 94.3 88.6-97.2 1858/1863 99.7 99.4-99.9 
Rhinovirus/Enterovirus 1986 268/294 91.2 87.4-93.9 1656/1692 97.9 97.1-98.5 
Influenza A 1978 242/244 99.2 97.0-99.8 1725/1734 99.5 99.0-99.7 
     Influenza A H1 1984 0/1 0.0 0.0-79.3 1983/1983 100.0 99.8-100.0 
     Influenza A H1N1\2009 1983 80/81 98.8 98.3-99.8 1897/1902 99.7 99.4-99.9 
     Influenza A H3 1981 156/157 99.4 93.3-99.8 1817/1824 99.6 99.2-99.8 
Influenza B 1983 122/129 94.6 89.2-97.3 1853/1854 99.9 99.7-100.0 
Parainfluenza Virus 1 1984 16/17 94.1 73.0-99.0 1964/1967 99.8 99.6-99.9 
Parainfluenza Virus 2 1984 2/2 100.0 34.2-100.0 1982/1982 100.0 99.8-100.0 
Parainfluenza Virus 3 1987 111/113 98.2 93.8-99.5 1869-1874 99.7 99.4-99.9 
Parainfluenza Virus 4 1984 3/3 100.0 43.8-100.0 1979-1981 99.9 99.6-100.0 
Respiratory Syncytial Virus 1985 212/220 96.4 93.0-98.1 1760/1765 99.7 99.3-99.9 
Bacteria 
Bordetella pertussis  1984 3/3 100.0 43.8-100.0 1975/1981 99.7 99.3-99.9 
Chlamydiophila 
pneumoniae 
1984 
5/5 100.0 56.6-100.0 1978/1979 99.9 99.7-100.0 
Mycoplasma  pneumoniae 1984 19/19 100.0 83.2-100.0 1960/1965 99.7 99.4-99.9 
a
These data are presented based on comparator assay (BioFire FilmArray Respiratory Panel 475 
version 1.7)  only and do not reflect any discordant analysis. Both the fresh and frozen samples 476 
are presented together as no differences in performance were determined statistically (data not 477 
shown). 478 
b
In instances where the internal control failed and was not resolved upon repeat, any target that 479 
was “Detected” was maintained within the data set and used in performance calculations. All 480 
targets that were not detected were considered failed and excluded from the data analysis 481 
therefore the final “N” will vary by analyte.  482 
  483 
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TABLE 3 Performance Summary of the QIAstat-Dx Respiratory Panel for Retrospective 484 
Specimens
a
  485 
Analyte 
 Positive Percent Agreement Negative Percent Agreement 
No,b TP/(TP + FN) % 95%CI TN/(TN + FP) % 95%CI 
Viruses 
Adenovirus 313 9/9 100.0 70.1-100.0 297/304 97.8 95.4-98,9 
Coronavirus 229E 313 26/27 96.3 81.7-99.3 286/286 100.0 98.7-100.0 
Coronavirus HKU1 313 14/14 100.0 78.5-100.0 298/299 99.7 98.1-99.9 
Coronavirus NL63 312 24/24 100.0 86.2-100.0 286/288 99.3 97.5-99.8 
Coronavirus OC43 310 28/28 100.0 87.9-100.0 282/282 100.0 98.6-100.0 
Human Metapneumovirus 313 2/2 100.0 34.2-100.0 311/311 100.0 98.7-100.0 
Rhinovirus/Enterovirus 313 44/49 89.8 78.2-95.5 254/264 96.2 92.3-97.9 
Influenza A 313 17/17 100.0 81.5-100.0 296/296 100.0 98.7-100.0 
     Influenza A H1 313 0/0 NA NA 313/313 100.0 98.8-100.0 
     Influenza A H1N1/2009 312 7/8 87.5 52.9-97.8 304/304 100.0 98.9-100.0 
     Influenza A H3 313 8/8 100.0 67.5-100.0 305/305 100.0 98.8-100.0 
Influenza B 313 1/1 100.0 20.7-100.0 312/312 100.0 98.8-100.0 
Parainfluenza Virus 1 307 40/40 100.0 91.2-100.0 267/267 100.0 98.8-100.0 
Parainfluenza Virus 2 312 3/3 100.0 100.0 309/309 100.0 98.8-100.0 
Parainfluenza Virus 3 313 1/4 25.0 4.6-69.9 309/309 100.0 98.8-100.0 
Parainfluenza Virus 4 302 22/24 91.7 74.2-97.7 278/278 100.0 98.6-100.0 
Respiratory Syncytial Virus 313 11/12 91,7 64.6-98.5 300/301 99.7 98.4-99.9 
Bacteria 
Bordetella pertussis  294 33/33 100.0 89.6-100.0 261/261 100.0 98.5-100.0 
Chlamydiophila 
pneumoniae 
311 
54/61 88.5 78.2-94.3 250/250 100.0 98.5-100.0 
Mycoplasma  pneumoniae 313 25/25 100.0 86.7-100.0 287/288 99.7 98.1-99.9 
a
These data are presented based on comparator assay (BioFire FilmArray Respiratory Panel 486 
version 1.7) only and do not reflect any discordant analysis.  487 
b
In instances where the internal control failed and was not resolved upon repeat, any target that 488 
was “Detected” was maintained within the data set and used in performance calculations. All 489 
targets that were not detected were considered failed and excluded from the data analysis 490 
therefore the final “N” will vary by analyte.  491 
  492 
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TABLE 4 Results of Discrepant Investigation for QIAstat-Dx Respiratory Panel (QDRP) -493 
Prospective and Retrospective Specimens 494 
 495 
Result Disposition based 
on initial testing versus 
comparator 
False Negativesa False Positives 
 
 
QDRP 
Result 
Discrepant Investigation 
Outcome: 
 
QDRP 
Result 
Discrepant Investigation 
Outcome: 
Analyte Total FN 
QDRP 
confirmedb 
(TN) 
QDRP 
unconfirmed 
(FN) Total FP 
QDRP 
confirmedb 
(TP) 
QDRP 
unconfirmed 
(FP) 
Viruses 
Adenovirusc 4 1 3 23 9 14 
Coronavirus 229E
d
 2 0 2 0 - - 
Coronavirus HKU1 1 1 0 8 0 8 
Coronavirus NL63
e
 7 0 7 4 1 3 
Coronavirus OC43
f
 3 3 0 4 3 1 
Human 
Metapneumovirus 
7 3 4 5 3 2 
Rhinovirus/Enterovirusg 31 9 22 46 18 28 
Influenza Ah 2 1 1 9 3 6 
     Influenza A H1i 1 0 1 0 - - 
     Influenza A H1/2009 2 0 2 5 3 2 
     Influenza A H3 1 0 1 7 7 0 
Influenza Bj 7 0 7 1 1 0 
Parainfluenza Virus 1 1 1 0 3 3 0 
Parainfluenza Virus 2 0 - - 0 - - 
Parainfluenza Virus 3 5 2 3 5 3 2 
Parainfluenza Virus 4 2 1 1 2 2 0 
Respiratory Syncytial 
Virus 
9 7 2 6 3 3 
Bacteria 
Bordetella pertussisk  0 - -- 6 1 5 
Chlamydiophila 
pneumoniael 
7 1 6 1 1 0 
Mycoplasma 
pneumoniaem 
0 - -- 6 1 5 
Total 92 30 62 141 62 79 
 496 
a
 Result disposition based on initial testing with QDRP versus comparator testing with BioFire 497 
FilmArray Respiratory Panel version 1.7. 498 
b
QIAstat-Dx RP  confirmed, the results of discrepant analysis supported the original QIAstat-Dx 499 
Respiratory Panel result as true negative or true positive.  QIAstat-Dx RP  unconfirmed, the 500 
results of discrepant analysis did not support the original QIAstat-Dx Respiratory Panel result 501 
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and result considered false negative or false positive. TN, true negative, FN, false negative; TP, 502 
true positive; FP, false positive. 503 
c
Two (2) FP adenovirus specimen did not undergo discordant analysis and were considered 504 
unconfirmed FP.  505 
d
Two (2) FN Coronavirus E229 specimen did not undergo discordant analysis and were 506 
considered unconfirmed FN.  507 
e
Two (2) FP Coronavirus NL63 specimen did not undergo discordant analysis and were 508 
considered unconfirmed FP.  509 
f
One (1) FN Coronavirus OC43 specimen did not undergo discordant analysis and was 510 
considered unconfirmed FN.  511 
g
Three (3) FN Rhinovirus/Enterovirus specimen did not undergo discordant analysis and were 512 
considered unconfirmed FN.  513 
h
Three (3) FP Influenza A samples were not available for discrepancy testing and were 514 
considered unconfirmed FP.  515 
i
Non-2009 H1 has not been in circulation since being replaced by the 2009 H1 and thus the 516 
discrepancy test result for the FN 2009-H1 sample is likely false 517 
j
One (1) FN Influenza B sample was not available for discrepancy testing and was considered 518 
unconfirmed FN.  519 
k
One (1) FP Bordetella pertussis sample was not available for discrepancy testing and was 520 
considered unconfirmed FP.  521 
l
Two  (2) FN Chlamydiophila pneumonia samples were not available for discrepancy testing and 522 
were considered unconfirmed FN.  523 
m
One  (1) FP Mycoplasma pneumoniae sample was not available for discrepancy testing and 524 
another FP (1) sample did not produce a valid result with the discrepancy method; both FP 525 
results were considered unconfirmed FP.  526 
 527 
 528 
 529 
 530 
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